Revenue Growth Remains Modest
Total revenue grew 1.2% year-over-year to $995.8M in Q1 FY2026, up from $984.2M in the prior-year period, suggesting stable but slow top-line momentum in CRL's core business segments.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: CRL posted modest 1.2% revenue growth to $995.8M in Q1 FY2026, but swung to a net loss of $14.8M despite a 60.6% surge in operating income, as heavy investing outflows and financing activity signal significant strategic repositioning.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue grew 1.2% year-over-year to $995.8M in Q1 FY2026, up from $984.2M in the prior-year period, suggesting stable but slow top-line momentum in CRL's core business segments.
Operating income jumped 60.6% to $119.9M from $74.7M, driven in part by a 10.3% reduction in SG&A expenses (from $177.8M to $159.4M), reflecting meaningful cost-cutting efforts that significantly expanded operating margin from 7.6% to 12.0%.
Despite strong operating performance, CRL reported a net loss of $14.8M compared to net income of $25.5M in Q1 FY2025, a swing of approximately $40.3M, likely driven by below-the-line charges such as interest expense, restructuring costs, or other non-operating items not captured in operating income.
Revenue
$995.83M
++1.18% YoY
EPS (Basic)
$-0.30
-160.00% YoY
Operating Income
$119.9M
++60.57% YoY
Add CRL to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.